MMSIMerit Medical Systems, Inc.

$87.39

The financials

Merit Medical Systems, Inc. by the numbers

Merit Medical Systems, Inc. (MMSI) reported revenue of $382M in Q1 2026 (quarter ended Mar 31, 2026), up 7.5% from the same quarter a year earlier. That came with a gross margin of 48% and net income of $41M (11% of revenue). For the full year FY2025, revenue was $1.52B (+12% year on year) and net income $128M. Its largest product in Jun 2026 was Therapeutic at $138M, 35% of the disclosed total, well ahead of Foundational Original Equipment Manufacturer at 12%.

Merit Medical Systems, Inc. income statement, Q1 2026 against the same quarter a year earlier
Income statementQ1 2026Q1 2025Change
Revenue$382M$355M+7.5%
Gross profit$185M$172M+7.4%
Operating income$44M$41M+7.6%
Net income$41M$30M+36%
Diluted EPS$0.68$0.49+39%
Revenue by product, Jun 2026, as reported to the SEC
ProductRevenueShare
Therapeutic$138M35%
Foundational Original Equipment Manufacturer$48M12%
Foundational Vascular Intervention$42M11%
Therapeutic Vascular Intervention$34M8.7%
Therapeutic Cardiac Therapies$29M7.2%
Foundational Procedural Solutions$28M7.1%
Therapeutic Oncology$26M6.5%
Therapeutic Endoscopy$24M6.0%
Therapeutic Original Equipment Manufacturer$13M3.2%
Therapeutic Renal Therapies$13M3.2%
Product And Service Other$1.2M0.3%

Business Segments

Revenue split by product segment, from SEC XBRL filings.

Latest period: Jun 2026Total $394.9M (+212%)
Product And Service Other grew +257% year on yearFoundational Procedural Solutions -12% year on year
  • Therapeutic$137.9MQoQ +9.1%year on year +15%
  • Foundational Original Equipment Manufacturer$48.3MQoQ -year on year +12%
  • Foundational Vascular Intervention$41.7MQoQ -year on year +19%
  • Therapeutic Vascular Intervention$34.4MQoQ -year on year +6.8%
  • Therapeutic Cardiac Therapies$28.5MQoQ -year on year +24%
  • Foundational Procedural Solutions$27.9MQoQ -year on year -12%
  • Therapeutic Oncology$25.8MQoQ -year on year +7.6%
  • Therapeutic Endoscopy$23.6MQoQ -year on year +29%
  • Therapeutic Original Equipment Manufacturer$12.8MQoQ -year on year +31%
  • Therapeutic Renal Therapies$12.7MQoQ -year on year -0.81%
  • Product And Service Other$1.2MQoQ -year on year +257%
Segment sum = 94% of reported consolidated revenue · Latest source: 10-Q filed 2026-07-30, SEC EDGAR